At Riverside, we put our patients’ health and well-being first. Our research team demonstrates this priority through our clinical trials by engaging in research that advances lifelong learning and evidence-based improvements in patient care. Currently, we have a range of ongoing clinical trials in Cardiology, Neurology, and Oncology. Our principal investigators have countless years of experience in study and research.
We are currently recruiting for the following clinical trials:
Oncology
- A011801 The COMPASSHER2 Residual Disease Trial A Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib
- A Survey and Registry Study of Patient Perceptions and Experiences with Oral Chemotherapy at a Community Hospital.
- An Observational Study of Triple Negative Breast Cancer at a Community Hospital
- Anal Cancer Study- EA2176: A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naïve Metastatic Anal Cancer Patients.
- “Connect” The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry
- DCP-001: Use of a Clinical Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
- IMPACTS PAIN management tool for Cancer Survivors_WF-1901: :Internet-delivered management of Pain Among Cancer Treatment Survivors (IMPACTS)
- OVERT Ovarian Cancer Clinical trial _AOA Dx: non-invasive blood test to assess the likelihood of ovarian malignancy
- Prospective Survey and Registry Study of Financial Toxicity in Cancer Patients Undergoing Radiotherapy in a Regional Cancer Center
Related: